Reference health
Sex differences in the hypothalamic–pituitary–adrenal axis: An obstacle to antidepressant drug development?
145/145 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
5 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 145 checked references that resolve
resolves10.1016/S0167-0115(00)00196-8
Vasopressinergic regulation of the hypothalamic–pituitary–adrenal axis: implications for stress adaptation
resolves10.1016/j.psyneuen.2006.12.013
Cognitive impairment associated to HPA axis hyperactivity after maternal separation in rats
resolves10.1038/sj.mp.4001250
Increased corticotropin-releasing hormone immunoreactivity in monoamine-containing pontine nuclei of depressed suicide men
resolves10.1038/mp.2010.66
Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology
resolves10.1038/mp.2012.24
Increased vulnerability of the brain norepinephrine system of females to corticotropin-releasing factor overexpression
resolves10.1016/j.yfrne.2014.03.008
Sex differences in stress-related psychiatric disorders: Neurobiological perspectives
resolves10.1007/s42000-018-0002-z
Sex differences in stress responses: a critical role for corticotropin-releasing factor
resolves10.1016/0924-977X(92)90019-5
CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse
resolves10.1038/nrd.2016.88
Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets
resolves10.1176/appi.ajp.2008.07071199
A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH
<sub>1</sub>
Antagonist) in the Treatment of Major Depression
resolves10.1038/sj.npp.1300191
Elevated Concentrations of CRF in the Locus Coeruleus of Depressed Subjects
resolves10.1097/JCP.0b013e3182239191
Efficacy and Safety of Mifepristone for the Treatment of Psychotic Depression
resolves10.1016/j.psyneuen.2012.05.001
Glucocorticoid sensitizers Bag1 and Ppid are regulated by adolescent stress in a sex-dependent manner
resolves10.1016/j.biopsych.2006.11.033
Major Depression in Late Life Is Associated with Both Hypo- and Hypercortisolemia
resolves10.1016/j.ejphar.2003.11.032
Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450
resolves10.1371/journal.pone.0072632
Inactivation of Glucocorticoid Receptor in Noradrenergic System Influences Anxiety- and Depressive-Like Behavior in Mice
resolves10.1038/sj.npp.1300875
Sexually Dimorphic Responses of the Brain Norepinephrine System to Stress and Corticotropin-Releasing Factor
resolves10.1006/hbeh.2000.1633
The Effects of Peptides on Partner Preference Formation Are Predicted by Habitat in Prairie Voles
resolves10.1176/ajp.150.4.656
Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression
resolves10.1016/j.neuroscience.2005.07.050
Sexual differentiation of central vasopressin and vasotocin systems in vertebrates: Different mechanisms, similar endpoints
resolves10.1038/sj.npp.1300002
Anxious–Retarded Depression: Relation with Plasma Vasopressin and Cortisol
resolves10.1210/endo.140.1.6415
The Impact of the Nonpeptide Corticotropin-Releasing Hormone Antagonist Antalarmin on Behavioral and Endocrine Responses to Stress**This research was supported by NIMH Grant MH-50479 and the Undergraduate Research Opportunities Program at the University of Colorado at Boulder.
resolves10.1016/j.biopsych.2006.05.034
Mifepristone versus Placebo in the Treatment of Psychosis in Patients with Psychotic Major Depression
resolves10.1016/j.yfrne.2015.04.003
Vasopressin and oxytocin receptor systems in the brain: Sex differences and sex-specific regulation of social behavior
resolves10.1016/S0306-4530(00)00040-8
Corticotropin-releasing hormone mRNA levels in response to chronic mild stress rise in male but not in female rats while tyrosine hydroxylase mRNA levels decrease in both sexes
resolves10.1007/s00213-016-4424-5
Effect of the CRF1-receptor antagonist pexacerfont on stress-induced eating and food craving
resolves10.1021/jm800744m
Synthesis and Pharmacological Characterization of Novel Druglike Corticotropin-Releasing Factor 1 Antagonists
resolves10.1111/j.1365-2265.1993.tb00522.x
Potentiation of the classic ovine corticotrophin releasing hormone stimulation test by the combined administration of small doses of lysine vasopressin
resolves10.1016/j.yfrne.2018.06.007
Improving pharmacological treatment in brain and mental health disorders: the need for gender and sex analyses
resolves10.1016/j.physbeh.2016.02.041
Depressive- and anxiety-like behaviors and stress-related neuronal activation in vasopressin-deficient female Brattleboro rats
resolves10.1210/endo-79-1-67
Further Studies on the Corticosteroid-Binding Globulin in the Rat: Proposed Endocrine Control
resolves10.1037/0278-6133.12.5.420
Sex differences in sensitivity of the hypothalamic-pituitary-adrenal axis.
resolves10.1038/celldisc.2016.12
An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology
resolves10.1046/j.1525-1381.1999.09423.x
The Endocrinology of Melancholic and Atypical Depression: Relation to Neurocircuitry and Somatic Consequences
resolves10.1038/npp.2012.136
Central Vasopressin V1A Receptor Blockade Impedes Hypothalamic–Pituitary–Adrenal Habituation to Repeated Restraint Stress Exposure in Adult Male Rats
resolves10.4088/JCP.12m07804
The Vasopressin V<sub>1b</sub>Receptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders
resolves10.2174/1381612053764797
Non-Peptide Vasopressin V1b Receptor Antagonists as Potential Drugs for the Treatment of Stress-Related Disorders
resolves10.1016/j.mce.2011.06.020
Mineralocorticoid and glucocorticoid receptors at the neuronal membrane, regulators of nongenomic corticosteroid signalling
resolves10.1016/j.psyneuen.2008.05.003
Behavioral effects of the CRF1 receptor antagonist R121919 in rats selectively bred for high and low activity in the swim test
resolves10.1002/neu.10157
Organizational effects of testosterone, estradiol, and dihydrotestosterone on vasopressin mRNA expression in the bed nucleus of the stria terminalis
resolves10.1016/j.yfrne.2013.11.001
Gonadal steroid hormones and the hypothalamo–pituitary–adrenal axis
resolves10.1093/nar/gkx1121
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
resolves10.1124/jpet.103.052092
Corticotropin-Releasing Factor in Brain: A Role in Activation, Arousal, and Affect Regulation
resolves10.3389/fendo.2016.00137
Paraventricular Hypothalamic Mechanisms of Chronic Stress Adaptation
resolves10.1002/(SICI)1520-6394(1998)8:2<71::AID-DA5>3.0.CO;2-N
Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: Response to amitriptyline treatment
resolves10.1016/j.pnpbp.2016.08.003
Mineralocorticoid receptor function in depressed patients and healthy individuals
resolves10.1196/annals.1286.038
High‐Quality Antidepressant Discovery by Understanding Stress Hormone Physiology
resolves10.1016/j.biopsych.2013.10.013
Sex Differences in Corticotropin-Releasing Factor Receptor-1 Action Within the Dorsal Raphe Nucleus in Stress Responsivity
resolves10.1038/sj.npp.1301328
High-Affinity CRF1 Receptor Antagonist NBI-34041: Preclinical and Clinical Data Suggest Safety and Efficacy in Attenuating Elevated Stress Response
resolves10.1177/0269881113499205
The role of mineralocorticoid receptor function in treatment-resistant depression
resolves10.1016/j.bbrc.2017.04.005
Sex difference in mouse hypothalamic transcriptome profile in stress-induced depression model
resolves10.1002/brb3.628
Hypothalamic‐pituitary‐adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one‐week randomized Phase 1b trial
resolves10.1055/s-2003-38092
The High-affinity Non-peptide CRH<sub>1</sub>Receptor Antagonist R121919 Attenuates Stress-induced Alterations in Plasma Oxytocin, Prolactin, and Testosterone Secretion in Rats
resolves10.1046/j.0953-816X.2000.01383.x
The anxiolytic effect of the CRH<sub>1</sub> receptor antagonist R121919 depends on innate emotionality in rats
resolves10.1016/j.jpsychires.2010.12.002
Decreased expression of mineralocorticoid receptor mRNA and its splice variants in postmortem brain regions of patients with major depressive disorder
resolves10.1002/jnr.23861
Preclinical sex differences in depression and antidepressant response: Implications for clinical research
resolves10.1016/j.neuropharm.2011.08.025
Behavioral sexual dimorphism in models of anxiety and depression due to changes in HPA axis activity
resolves10.1016/j.psyneuen.2017.10.007
Sex differences in behavioral and neurochemical effects of gonadectomy and aromatase inhibition in rats
resolves10.1016/j.neuroscience.2011.07.077
Citalopram-mediated anxiolysis and differing neurobiological responses in both sexes of a genetic model of depression
resolves10.1523/JNEUROSCI.20-10-03843.2000
Glucocorticoid Negative Feedback Selectively Targets Vasopressin Transcription in Parvocellular Neurosecretory Neurons
resolves10.1016/S0022-3956(03)00070-0
Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects
resolves10.1016/S0022-3956(02)00009-2
The CRH1 receptor antagonist R121919 attenuates stress-elicited sleep disturbances in rats, particularly in those with high innate anxiety
resolves10.3389/fnsys.2013.00100
A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study
resolves10.1016/j.psyneuen.2012.05.006
The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary–adrenal activity in humans with psychotic major depression
resolves10.1371/journal.pone.0028376
Mifepristone Prevents Stress-Induced Apoptosis in Newborn Neurons and Increases AMPA Receptor Expression in the Dentate Gyrus of C57/BL6 Mice
resolves10.1016/j.neuroscience.2015.08.024
Effects of early-life stress on cognitive function and hippocampal structure in female rodents
resolves10.1016/j.neuropharm.2016.01.033
Ovarian hormones, but not fluoxetine, impart resilience within a chronic unpredictable stress model in middle-aged female rats
resolves10.1016/S0014-2999(97)00025-3
Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist
resolves10.1016/0006-2952(87)90234-6
Glucocorticoid-biogenic amine interactions in relation to mood and behavior
resolves10.1210/endo-94-6-1628
Spironolactone and Testicular Cytochrome P-450: Decreased Testosterone Formation inSeveral Species and Changes in Hepatic Drug Metabolism<sup>1</sup>
resolves10.1056/NEJM199307223290429
Women in Clinical Trials of New Drugs -- A Change in Food and Drug Administration Policy
resolves10.1016/j.biopsych.2017.10.012
Corticotropin-Releasing Factor Type 1 Receptor Antagonists for Stress-Related Disorders: Time to Call It Quits?
resolves10.1210/jcem-61-3-536
Successful Treatment of Cushing’s Syndrome with the Glucocorticoid Antagonist RU 486*
resolves10.1016/j.psyneuen.2017.02.012
Lower allopregnanolone during pregnancy predicts postpartum depression: An exploratory study
resolves10.1016/j.jpsychires.2009.10.006
Modulation of the mineralocorticoid receptor as add-on treatment in depression: A randomized, double-blind, placebo-controlled proof-of-concept study
resolves10.1080/10253890.2017.1369523
Hypothalamic–pituitary–adrenal and hypothalamic–pituitary–gonadal axes: sex differences in regulation of stress responsivity
resolves10.1016/j.yfrne.2014.03.002
Development of the HPA axis: Where and when do sex differences manifest?
resolves10.1097/01.PSY.0000088594.17747.2E
Cortisol Responses to Daily Events in Major Depressive Disorder
resolves10.1186/s13293-018-0192-8
Sex differences in the traumatic stress response: the role of adult gonadal hormones
resolves10.1001/archpsyc.1996.01830020055007
Increased Number of Vasopressin- and Oxytocin-Expressing Neurons in the Paraventricular Nucleus of the Hypothalamus in Depression
resolves10.1016/j.steroids.2017.12.005
Membrane-initiated nuclear trafficking of the glucocorticoid receptor in hypothalamic neurons
resolves10.1016/S0091-3057(99)00148-3
Gender, Sex Steroids, Corticotropin-Releasing Factor, Nitric Oxide, and the HPA Response to Stress
resolves10.1111/j.1365-2826.2006.01516.x
Neuroendocrinological Mechanisms of Actions of Antidepressant Drugs
resolves10.1073/pnas.93.19.10477
CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.
resolves10.1016/S0168-0102(03)00056-7
Gonadal and adrenal effects on the glucocorticoid receptor in the rat hippocampus, with special reference to regulation by estrogen from an immunohistochemical view-point
resolves10.1016/j.neuroscience.2011.12.014
Deletion of forebrain glucocorticoid receptors impairs neuroendocrine stress responses and induces depression-like behavior in males but not females
resolves10.1210/en.2015-1276
Neuroendocrine Function After Hypothalamic Depletion of Glucocorticoid Receptors in Male and Female Mice
resolves10.1016/j.psyneuen.2018.04.012
Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis
resolves10.1210/en.2002-220556
Sexually Dimorphic Expression of Corticotropin-Releasing Hormone-Binding Protein in the Mouse Pituitary
resolves10.1007/s00213-017-4556-2
Don’t stress about CRF: assessing the translational failures of CRF1antagonists
resolves10.1016/j.psyneuen.2014.09.009
Hypothalamic vasopressin systems are more sensitive to the long term effects of social defeat in males versus females
resolves10.1002/jnr.22737
Sex‐dependent and differential responses to acute restraint stress of corticotropin‐releasing factor–producing neurons in the rat paraventricular nucleus, central amygdala, and bed nucleus of the stria terminalis
resolves10.1016/j.psyneuen.2016.08.019
Progesterone: The neglected hormone in schizophrenia? A focus on progesterone-dopamine interactions
resolves10.1177/0956797609356507
Are Plasma Oxytocin in Women and Plasma Vasopressin in Men Biomarkers of Distressed Pair-Bond Relationships?
resolves10.1111/j.1460-9568.2012.08237.x
Sex differences in fear memory and extinction of mice with forebrain‐specific disruption of the mineralocorticoid receptor
resolves10.1016/S0165-1781(97)00106-6
Effects of antidepressant treatment on corticotropin-induced cortisol responses in patients with melancholic depression
resolves10.1016/j.neubiorev.2005.04.014
The role of CRF receptors in anxiety and depression: Implications of the novel CRF1 agonist cortagine
resolves10.1016/j.brainres.2011.09.004
The CRH-R1 receptor mediates luteinizing hormone, prolactin, corticosterone and progesterone secretion induced by restraint stress in estrogen-primed rats
resolves10.1210/jc.81.7.2468
Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol
resolves10.7326/0003-4819-114-2-143
Rapid Reversal of Acute Psychosis in the Cushing Syndrome with the Cortisol-Receptor Antagonist Mifepristone (RU 486)
resolves10.1016/S0893-133X(97)00054-7
Plasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression
resolves10.1016/j.yhbeh.2010.03.006
Distinct correlations of vasopressin release within the lateral septum and the bed nucleus of the stria terminalis with the display of intermale aggression
resolves10.1210/en.2004-0846
Gender and Puberty Interact on the Stress-Induced Activation of Parvocellular Neurosecretory Neurons and Corticotropin-Releasing Hormone Messenger Ribonucleic Acid Expression in the Rat
resolves10.1016/j.neuropharm.2018.09.037
The effect of acute or repeated stress on the corticotropin releasing factor system in the CRH-IRES-Cre mouse: A validation study
resolves10.1002/jcb.26040
The Non‐Peptide Vasopressin V1b Receptor Antagonist, SSR149415, Ameliorates Spermatogenesis Function in a Mouse Model of Chronic Social Defeat Stress
resolves10.3109/00016349509021201
Treatment of premenstrual syndrome by spironolactone: A double‐blind, placebo‐controlled study
resolves10.1016/j.neuropharm.2011.09.014
Hippocampal GR expression is increased in elderly depressed females
resolves10.1007/s00429-013-0589-4
Distribution of the glucocorticoid receptor in the human amygdala; changes in mood disorder patients
resolves10.1038/mp.2008.38
Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances
resolves10.1016/j.biopsych.2012.05.029
A Randomized Trial to Examine the Effect of Mifepristone on Neuropsychological Performance and Mood in Patients with Bipolar Depression
resolves10.1002/cne.23475
Sex‐ and region‐specific pubertal maturation of the corticotropin‐releasing factor receptor system in the rat
resolves10.3389/fpsyt.2014.00179
A Review of the Role of Social Cognition in Major Depressive Disorder
resolves10.1016/j.expneurol.2011.04.012
Ovarian hormones influence corticotropin releasing factor receptor colocalization with delta opioid receptors in CA1 pyramidal cell dendrites
resolves10.3758/s13415-016-0441-4
Effects of mineralocorticoid receptor blockade on empathy in patients with major depressive disorder
resolves10.1037/0735-7044.115.1.175
The contribution of adrenal and reproductive hormones to the opposing effects of stress on trace conditioning males versus females.
resolves10.1038/sj.npp.1301386
Mifepristone Repairs Region-Dependent Alteration of Synapsin I in Hippocampus in Rat Model of Depression
resolves10.1016/j.psyneuen.2012.09.011
Mineralocorticoid receptor antagonist spironolactone prevents chronic corticosterone induced depression-like behavior
resolves10.1016/S0893-133X(00)00236-0
Twenty-Four-Hour ACTH and Cortisol Pulsatility in Depressed Women
resolves10.1001/archpsyc.1993.01820170073010
Dissociation Between Pituitary and Adrenal Suppression to Dexamethasone in Depression
resolves10.1210/jc.83.9.3339
The Role of Mineralocorticoid Receptors in Hypothalamic-Pituitary-Adrenal Axis Regulation in Humans
resolves10.1016/j.brainresbull.2004.04.007
Effects of repeated restraint stress on hypothalamo-pituitary-adrenocortical function in vasopressin deficient Brattleboro rats
resolves10.1176/appi.ajp.162.7.1370
Generalizability of Antidepressant Efficacy Trials: Differences Between Depressed Psychiatric Outpatients Who Would or Would Not Qualify for an Efficacy Trial
resolves10.1016/S0022-3956(00)00016-9
Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated
resolves10.1016/S0006-8993(02)03189-X
Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat
The 5 references without a DOI — listed, not checked
no DOI — not checkedPossible use of glucocorticoid receptor antagonists in the treatment of major depression: Preliminary results using RU 486
no DOI — not checkedVan Gaalen M. M. Basso A. M. Bespalov A. Y. Rueter L. E. Oost T. Breuer M. …Sullivan J. P.(2008).Antidepressant‐and anxiolytic‐like effects of the vasopressin V1b receptor antagonists ABT‐436 and ABT‐558. Proceedings of Society for Neuroscience Washington DC USA Abstract 560.
no DOI — not checkedReceptor activity modifying protein‐directed G protein signaling specificity for the calcitonin gene‐related peptide family of receptors
no DOI — not checkedThe role of gonadal steroids in hypothalamic‐pituitary‐adrenal axis regulation
no DOI — not checkedSex differences and the HPA axis: Implications for psychiatric disease
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1111/bph.14710"><img src="https://citestamp.com/citestamped/10.1111/bph.14710/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1111/bph.14710)